Table 1.
Baseline patient characteristics a .
| Characteristic | Unweighted population | IPTW-weighted population | ||||
|---|---|---|---|---|---|---|
| Low-HR/ HER2-negative |
TNBC | SMD | Low-HR/ HER2-negative |
TNBC | SMD | |
| N=70 (%) | N=218 (%) | N=287.5 (%) | N=288.03 (%) | |||
| Age, year (mean(SD)) | ||||||
| 48.37 (9.87) | 47.59 (9.72) | 0.080 | 47.59 (9.63) | 47.75 (9.71) | 0.016 | |
| Menopausal status | ||||||
| Postmenopausal | 31 (44.3) | 85 (39.0) | 0.108 | 110.0 (38.3) | 115.5 (40.1) | 0.038 |
| Premenopausal | 39 (55.7) | 133 (61.0) | 177.4 (61.7) | 172.5 (59.9) | ||
| Clinical tumour stage | ||||||
| T1-2 | 50 (71.4) | 141 (64.7) | 0.145 | 191.7 (66.7) | 191.1 (66.4) | 0.007 |
| T3-4 | 20 (28.6) | 77 (35.3) | 95.7 (33.3) | 96.9 (33.6) | ||
| Pathological nodal status | ||||||
| N0 | 22 (31.4) | 80 (36.7) | 0.111 | 94.0 (32.7) | 101.6 (35.3) | 0.055 |
| N+ | 48 (68.6) | 138 (63.3) | 193.4 (67.3) | 186.4 (64.7) | ||
| Histological tumour type | ||||||
| IDC | 66 (94.3) | 195 (89.4) | 0.178 | 258.3 (89.9) | 260.9 (90.6) | 0.024 |
| Other | 4 (5.7) | 23 (10.6) | 29.1 (10.1) | 27.2 (9.4) | ||
| Tumour grade | ||||||
| II | 38 (54.3) | 103 (47.2) | 0.251 | 144.9 (50.4) | 141.5 (49.1) | 0.031 |
| III | 27 (38.6) | 83 (38.1) | 105.0 (36.5) | 109.5 (38.0) | ||
| Unknown | 5 (7.1) | 32 (14.7) | 37.5 (13.1) | 37.0 (12.9) | ||
a
Low-HR/HER2-negative, low hormone receptor/human epidermal growth factor receptor 2 negative; TNBC, triple-negative breast cancer; SMD, std mean difference; SD, standard deviation; IDC, invasive ductal carcinoma.